| Pharmaceutical Information |
| Drug Name |
Ixabepilone |
| Drug ID |
BADD_D01222 |
| Description |
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. |
| Indications and Usage |
Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified). |
| Marketing Status |
approved; investigational |
| ATC Code |
L01DC04 |
| DrugBank ID |
DB04845
|
| KEGG ID |
D04645
|
| MeSH ID |
C430592
|
| PubChem ID |
6445540
|
| TTD Drug ID |
D0W2EK
|
| NDC Product Code |
70020-1910; 66499-0053; 70020-1911; 62158-0008 |
| UNII |
K27005NP0A
|
| Synonyms |
ixabepilone | azaepothilone B | BMS247550 | BMS 247550 | BMS-247550 |
|
| Chemical Information |
| Molecular Formula |
C27H42N2O5S |
| CAS Registry Number |
219989-84-1 |
| SMILES |
CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
